StageDead | Dead
About Neose Technologies
Neose Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapeutic proteins that are competitive with best-in-class protein drugs currently on the market. The lead candidates in the company's pipeline, GlycoPEG-GCSF for chemotherapy-induced neutropenia, and GlycoPEGylated Factors VIIa, VIII and IX for hemophilia, target markets with 2006 aggregate sales of approximately $8 billion.
Missing: Neose Technologies's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Neose Technologies's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Neose Technologies Patents
Neose Technologies has filed 3 patents.
EC 2.4.1, Transferases, Clusters of differentiation
EC 2.4.1, Transferases, Clusters of differentiation
Latest Neose Technologies News
May 16, 2016
By Nick TaylorNick Taylor , 18-Sep-20082008-09-18T00:00:00Z Related tags: BioGeneriX, Novo, Neose, PEGylation BioGeneriX and Novo Nordisk have signed deals to acquire most of Neose Technologies’ intellectual property for a combined total of $43m. Neose was already in developmental collaborations with BioGeneriX and Novo but has faced a difficult 12 months following the demise of its lead drug candidate in 2007. The company made a $28.5m loss last year, compared with a loss of $27.1m in the previous year. Earlier this year the company outlined its plans to refocus its R&D and highlighted its PEGylation collaborations with BioGeneriX and Novo as projects that were progressing well. However, Neose has now decided that the best way to maximise stockholder value and increase the likelihood of the products getting to market is to sell its assets. George Vergis, Neose’s CEO, said: “The announcement of these asset sales follows an extensive review of a range of strategic alternatives for the company, including obtaining further financing to continue as an independent entity and exploring mergers and acquisitions. “We believe that the sale of these assets to our existing collaborative partners maximizes stockholder value and increases the probability that patients will benefit from the continued development of drug candidates that incorporate our intellectual property, including GlycoPEG-GCSF and GlycoPEGylated Factors VIIa, VIII and IX.” Neose is a specialist in the PEGylation of proteins, which is a technology that enables the extension and customisation of a protein’s half-life. This is achieved by linking various size PEG polymers to glycans. The company has developed a library of enzymes for PEGylation that it produces in fungal and other expression systems. It has also developed technology to produce sugar nucleotides in large quantities. Using this technology Neose has developed neutropenia treatment GlycoPEG-GCSF with BioGeneriX. Positive Phase I data was released by the companies in November 2007, leading to Phase II trials being launched in June. Neose’s collaboration with Novo developed GlycoPEGylated Factors VIIa, VIII and IX for the treatment of haemophilia. Factor VIIa is the most developmentally advanced of the three treatments and entered into Phase I clinical trials in June 2007. Novo has spent about $21m to acquire the intellectual property for the treatments, which it views as being inline with its policy of expanding its presence within haemophilia treatments. Neose has retained certain intellectual property rights, including those related to the production of glycolipids. Although it is to retain these rights, liquidation of the company is being considered if stockholders approve. This content is copyright protected However, if you would like to share the information in this article, you may use the headline, summary and link below: Neose sells PEG tech for $43m By Nick TaylorNick Taylor, 18-Sep-2008 BioGeneriX and Novo Nordisk have signed deals to acquire most of Neose Technologies’ intellectual property for a combined total of $43m. Copyright - Unless otherwise stated all contents of this web site are © 2016 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions Related news:
Neose Technologies Frequently Asked Questions (FAQ)
When was Neose Technologies founded?
Neose Technologies was founded in 1989.
Where is Neose Technologies's headquarters?
Neose Technologies's headquarters is located at 102 Rock Road, Horsham.
What is Neose Technologies's latest funding round?
Neose Technologies's latest funding round is Dead.
How much did Neose Technologies raise?
Neose Technologies raised a total of $89.51M.
Who are the investors of Neose Technologies?
Investors of Neose Technologies include Novo Nordisk, Paramount Capital Asset Management, OrbiMed Advisors, Domain Associates, MHR Fund Management and 25 more.
Who are Neose Technologies's competitors?
Competitors of Neose Technologies include Cerecin, Pfenex, AM-Pharma, Array Biopharma, XenoPort and 11 more.
Compare Neose Technologies to Competitors
Serentis is a biopharmaceutical company which aims to develop a pipeline of products to address unmet medical needs in the dermatology field. The company's strategy is to establish a clinical stage development pipeline by the reprofiling of existing drugs and through the licensing or acquisition of projects from external sources. This is an approach that Serentis' management team has successfully pursued in the past.
Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.
Hawaii Biotech (HBI) is a privately held biotechnology company focused on the research and development of vaccines for established and emerging infectious diseases. The company has developed expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. Lead vaccine candidates in clinical development target the West Nile virus and Dengue virus. Additional recombinant protein subunits vaccine candidates produced from this protein production platform are currently under development.
Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company's strategy is to develop new drugs that it derives from natural substances used therapeutically in non-western medical practice. Bionovo's first drug is entering phase II clinical testing for menopause, its second has completed phase I clinical testing for cancer, and these are followed by more than forty additional drug candidates that the company believes should provide Bionovo with a sustainable development pipeline of new chemical entities and botanicals.
Founded in 2005 Ora Bio Ltd, a biopharmaceutical company, is engaged in the repositioning of existing drugs for second-use applications. nnThe Company is developing its two products, the ORA101 and ORA102, as drugs for non-small cell lung cancer (NSCLC) and age-related macular degeneration (AMD) respectively. Both the company's products are currently in Phase II clinical trials.n
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.